Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06291935RecruitingPhase 1
Gene therapy trial for retinitis pigmentosa with CNGA1 mutation
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
TübingenAges 18 years+ - NCT05477849RecruitingPhase 1
Study drug for people with advanced solid tumors
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hangzhou, ZhejiangAges 18–75 - NCT07233811Recruiting
Same-day discharge after robotic hysterectomy
This trial tests if it's safe and beneficial to go home the same day after robotic hysterectomy, compared to staying overnight. It includes women with both benign conditions and endometrial cancer, regardless of weight or uterus size.
StockholmAges 18–75 - NCT07224763RecruitingPhase 1/Phase 2
Pig kidney transplant trial for kidney failure patients
This trial tests a genetically modified pig kidney (Thymokidney) for people with end-stage kidney disease who are on dialysis. It aims to see if this new type of transplant is safe and effective for those who cannot get a human kidney.
New York, New YorkAges 40–70 - NCT07229742RecruitingPhase 2
Study of SHR-2173 for active lupus nephritis
This trial tests a new medicine called SHR-2173 for people with active lupus nephritis, a kidney inflammation caused by lupus. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70 - NCT07220876Recruiting
VisiPlate implant for hard-to-control open-angle glaucoma
This trial tests a new device called VisiPlate that is placed in the eye to help lower pressure for people with hard-to-control open-angle glaucoma. It may be an option if standard treatments haven't worked well enough.
Glendale, ArizonaAges 45 years+ - NCT07169214RecruitingPhase 1
Study of BT-114143 injection for heavy menstrual bleeding
This trial tests an investigational medication called BT-114143 for people with heavy menstrual bleeding (abnormal uterine bleeding). The goal is to see if it is safe and effective in reducing blood loss during periods.
Beijing, Beijing MunicipalityAges 18–50 - NCT07158775RecruitingPhase 1/Phase 2
BS01 gene therapy for dry age-related macular degeneration
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Edison, New JerseyAges 50–85 - NCT07147114RecruitingPhase 4
Combined macitentan and dapagliflozin for heart failure with lung high blood pressure
This trial tests whether adding two medications—macitentan and dapagliflozin—together is safe and effective for people with heart failure and a certain type of high blood pressure in the lungs. It might help improve your symptoms and daily function.
BusanAges 19 years+ - NCT07152366RecruitingPhase 4
Hormone and tetuzumab for active thyroid eye disease
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06752746RecruitingPhase 1
Testing 9MW3011 for polycythemia vera in resistant patients
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
Zhengzhou, HenanAges 18 years+ - NCT07110415RecruitingPhase 4
Yangxinshi tablets for heart disease with reduced heart function
This trial tests whether Yangxinshi tablets can help people with coronary heart disease and some degree of heart failure. It looks at improving heart function and safety over the treatment period.
Haozhou, AnhuiAges 40–80 - NCT07090759RecruitingPhase 3
Test of new drug for hepatitis B not fully controlled by current treatment
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
Hangzhou, ZhejiangAges 18–70 - NCT07093476RecruitingPhase 3
Adding empagliflozin to improve blood sugar control
This trial tests whether adding empagliflozin (a diabetes pill) to your current medicines (alogliptin and metformin) helps manage blood sugar better. It may be an option if your blood sugar is not well controlled with your current treatment.
SeoulAges 19 years+ - NCT07088081Enrolling by invitation
Immunotherapy drugs for advanced liver cancer
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
Cairo, AbbasyaAges 18 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT07082192RecruitingPhase 2/Phase 3
Testing CB03-154 for adults with ALS
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
Beijing, Beijing MunicipalityAges 18–65 - NCT07084012RecruitingPhase 2
Stem cell treatment for recent stroke
This trial tests whether a single infusion of umbilical cord stem cells can help people recover from a recent ischemic stroke (stroke caused by a clot). It is for patients who have had their stroke within the last 72 hours and have moderate to severe symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07066826RecruitingPhase 2/Phase 3
Huperzine A for mild-to-moderate Alzheimer's dementia
This study tests whether Huperzine A controlled-release tablets can help improve memory and thinking in people with mild-to-moderate Alzheimer's disease. You'll take the tablets or a placebo to see if it slows down dementia symptoms.
BeijingAges 50–85 - NCT07074496RecruitingEarly Phase 1
Combined cell therapy for newly diagnosed Ph+ ALL
This trial tests a new combination treatment using ThisCART19A cells and olverembatinib in adults newly diagnosed with a type of leukemia that has the Philadelphia chromosome. It aims to see if this approach is safe and effective.
Suzhou, JiangsuAges 18 years+ - NCT07056777RecruitingPhase 1/Phase 2
DR30206 plus standard therapy for advanced GI cancer
This trial tests a new drug called DR30206 combined with standard therapy for advanced gastrointestinal cancers. It may be an option if you have colorectal, esophageal, gastric, or gastroesophageal junction cancer and have had little or no prior chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07051707Recruiting
Study of a new lung treatment for people with COPD
This trial tests a device called dNerva that targets nerves in the lungs to help people with COPD breathe easier. It is designed for those who have moderate to severe COPD and are not currently smoking.
Birmingham, AlabamaAges 40–80 - NCT07036172RecruitingPhase 3
Semaglutide vs Wegovy for weight loss in Chinese adults
This trial compares a semaglutide injection to the already-approved weight loss drug Wegovy in Chinese adults with obesity. It aims to see if the new option works just as well to help people lose weight.
BeijingAges 18–75 - NCT07037446Enrolling by invitation
Occlutech leak device for mitral or aortic paravalvular leaks
This registry tracks the safety and effectiveness of a device designed to close leaks around heart valves (mitral or aortic). It may be an option for people who have significant symptoms like heart failure or anemia from these leaks and are not good candidates for surgery.
KatowiceAges 18 years+
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,317 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.